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OBJECTIVE: Advanced and inoperable solid tumours in children have high mortality despite aggressive
multimodal treatment. Intravenous chemotherapy is abandoned at times because of systemic toxicity.
This study investigated intratumoural chemotherapy and compared it with intravenous chemotherapy.
METHODS: Forty children with advanced inoperable solid tumours (Wilms’ tumour and neuroblastoma)
were randomly allocated into two groups of 20. Group A was given intratumoural chemotherapy and
group B was given intravenous chemotherapy. Both groups were compared for reduction in tumour size
and volume, tumour resectability, histopathological changes and drug side effects.
RESULTS: Intratumoural chemotherapy was superior to intravenous chemotherapy in terms of reduc-
ing tumour size and volume (63% in group A vs. 22% in group B). The resectability was 70% in the intra-
tumoural group compared with 40% in the intravenous group. The overall good histopathological
response was 71% in group A as opposed to 0% in group B. Moreover, the incidence and severity of drug
side effects and morbidity were less with intratumoural chemotherapy. Mortality was also low in group A
(5%) compared to group B (20%).
CONCLUSION: Intratumoural chemotherapy can be offered as an effective and safe alternative treat-
ment modality for advanced and inoperable Wilms’ tumour and neuroblastoma. [Asian J Surg 2008;
31(4):225–9]
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Introduction
Advanced and inoperable solid tumours in children have
a high mortality rate despite aggressive multimodal 
treatment. Most solid tumours in children under 15 years
of age are neuroblastoma, Wilms’ tumour, lymphoma and
rhabdomyosarcoma. These account for 28.1% of all child
cancers and their incidence is 7.3%, 6.1%, 11.3% and 3.4%,
respectively.1,2 Since apart from lymphoma, Wilms’ tumour
and neuroblastoma comprise > 80% of all solid childhood
malignancies, we concentrated our study only on Wilms’
tumour and neuroblastoma.
In our study, due to their illiteracy and lower socio-
economic status, patients with Wilms’ tumour and neuro-
blastoma tended to present at an advanced stage and were
inoperable at the time of initial presentation. Although
there have been many advances with the collaboration of
paediatric oncologists, surgeons and radiotherapists, the
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prognosis for advanced solid malignancies in children
remains poor.3–5 Some improvement in survival has been
noted by alternating effective chemotherapeutic agents to
overcome or prevent resistance, and by continuous infu-
sion rather than bolus administration of drugs.6,7 Alter-
native routes of administration of chemotherapeutic
agents have been tried for advanced solid tumours, mostly
for palliation. In 1976, intra-arterial transcatheter occlu-
sion of abdominal tumours was tried by Goldstein et al.8
Intra-arterial chemotherapy has been tried for hepatocel-
lular carcinoma, and advanced pancreatic, breast and liver
metastases from colorectal carcinoma.9–17 Intraperitoneal
chemotherapy has also shown promising antitumour effi-
cacy against ovarian carcinoma, peritoneal carcinomatosis
and advanced gastric carcinoma.18–20 However, all these
studies were restricted to adults. Livraghi et al21,22 reported
fine needle percutaneous intratumoural chemotherapy
under ultrasound guidance in 12 selected adult patients
with tumours that did not respond to conventional treat-
ment. Partial or total pain control, disease stability and
response were observed in 60% of patients. They con-
cluded that intratumoural chemotherapy may be an alter-
native treatment for tumours that are unresponsive to
conventional chemotherapy.
An extensive literature search failed to find any stud-
ies on intratumoural chemotherapy in paediatric solid 
tumours. Therefore, our study was a pilot study of
intratumoural chemotherapy in advanced solid tumours
in children. 
Methods
The study was conducted in the Department of Paediatric
Surgery with cooperation from the Department of
Radiology and the Department of Pathology at University
Hospital, Varanasi. The period of study was from July
2000 to June 2004. Forty patients with advanced inopera-
ble solid tumours, nephroblastoma and neuroblastoma,
were randomly allocated into two groups (A and B) of 20
patients, after confirming diagnosis by fine needle aspira-
tion cytology. Group A consisted of 13 patients with
Wilms’ tumour and seven with neuroblastoma. Patients
were treated with intratumoural vincristine (1.5 mg/m2),
actinomycin D (45 μg/kg) and adriamycin (50 mg/m2)
through a 26 G spinal needle under aseptic conditions
and ultrasound guidance, at the same doses and schedule
as used for standard systemic chemotherapy. Adriamycin
and actinomycin D were given as a single dose while vin-
cristine was given weekly for 6 weeks. An injection of
hyaluronidase was added to the drugs to enhance their
local distribution. Group B consisted of 14 patients with
Wilms’ tumour and six with neuroblastoma. Patients were
treated with intravenous chemotherapy with the same
doses and schedule as for group A.
All patients were evaluated by two senior consultants by
clinical examination, sonography and computed tomogra-
phy to establish the inoperability of the tumour. The tumour
volume under ultrasound guidance was calculated by the
formula: 0.523 × the product of the three dimensions of the
tumour. Patients were evaluated before, during and after
chemotherapy as per the set pro forma. The symptoms and
drug side effects in both groups were noted. Supportive
therapy was given in the form of whole blood, platelet con-
centrate and fresh frozen plasma as and when required.
After removal of the tumour, both groups received
intravenous chemotherapy as per standard schedule
(NWTS protocol). Ten slides from each specimen were
taken for detailed microscopic examination, to compare
various histopathological changes that occurred follow-
ing chemotherapy.
Z value was calculated, using the following equation,
for statistical analysis. 
where P1 is the proportion in the first sample, P2 is the
proportion in the second sample, n1 is the size of the first
sample, n2 is the size of the second sample, q1 = 1 − P1 and
q2 = 1 − P2. If Z was > 1.96, then it was significant at 5%
(p < 0.05).
Results
Reduction in tumour size and volume
Intratumoural chemotherapy was superior to intravenous
chemotherapy in terms of reducing tumour size (Figure 1)
and volume, and down-staging the tumour to allow
resectability.
Resectability and histological response
The resected specimens were examined histopathologi-
cally and divided into three groups on the basis of Zuppan
criteria.23 Type I, good response: microscopic examination
showed extensive necrosis, focal fibrosis and inflammatory
Z
P P
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cells, which were mainly eosinophilic. There was also haem-
orrhage, hyaline degeneration and soft tissue. No malignant
cells were detected in any tissue sections. Type II, partial
response: microscopy revealed predominance of atrophic
dilated glands with scanty blastemal/tumour cells. Angi-
omatous malformations were also seen in some sections.
Type III, non responders: focal areas of mainly blastemal/
tumour cells, with few glands separated by dense fibrocol-
lagenous tissue. There were no inflammatory cells, necrosis
or haemorrhage.
In nine out of 13 patients (69%) in group A with
Wilms’ tumour, surgical resection was possible after
intratumoural chemotherapy. Six (67%) of these showed 
a good response according to histopathological criteria,
while two (22%) had a partial response and the remaining
patient (11%) had no response. In five out of seven
patients (72%) in group A with neuroblastoma, surgical
resection was possible after completion of intratumoural
chemotherapy. Four of these (80%) responded well and
one patient (20%) had a partial response (Figures 2 and 3).
Overall, the good response rate according to histopatho-
logical criteria was 71% in group A and 0% in group B
(Figure 4). The Z value of 5.90 was statistically significant. 
Side effects of chemotherapy
The incidence and severity of side effects was low in group
A. Moreover, although chemotherapy can lead to severe
anaemia and pancytopenia, the requirement for blood
transfusion was also low in group A in comparison to
group B (Table).
Discussion
Advanced and inoperable solid tumours in children are
difficult to manage in spite of advances in cancer research,
mainly because advanced disease leads to a poor general
condition and intolerance of multimodal therapy. The
International Society of Paediatric Oncology (SIOP) has
promoted the use of preoperative chemotherapy with or
without radiotherapy to increase tumour resectability and
to minimize surgical complications.24,25 The response to
A B
Figure 1. A case of Wilms’ tumour in the intratumoural chemother-
apy group that was reduced in size after treatment.
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Figure 2. Resectability and outcome after two modalities of
chemotherapy.
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Figure 3. Histological response to two modalities of chemotherapy.
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Figure 4. Overall histopathological response to two modalities
of chemotherapy.
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conventional intravenous chemotherapy is varied due to
systemic spread of disease and poor tolerance of already
malnourished patients leading to postponement of
chemotherapy in between.
In our study, intratumoural chemotherapy produced
better and earlier tumour regression than intravenous
chemotherapy, measured both by clinical examination
(tumour size) and ultrasonography (tumour volume).
This finding was statistically significant in patients who
had responded to chemotherapy (> 50% reduction in
tumour volume) (Figure 5).
Tumours in 70% of patients in group A were success-
fully excised after one course (6 weeks) of intratumoural
chemotherapy in comparison to only 40% in the intra-
venous chemotherapy group (group B). Unlike patients
with intravenous chemotherapy, those who received intra-
tumoural chemotherapy did not have much adhesion
with any of the surrounding tissue, which suggested that
the drugs did not extravasate from the tumour, and it was
a safe method. It was observed during surgery that 
neovascularization and oedema were significantly less in
the intratumoural group as compared with the intra-
venous group, which may have been caused by the high
concentration of chemotherapeutic drugs acting on target
tumour cells.
Seven patients in group A who presented with metas-
tasis, e.g. tumour thrombus in the inferior vena cava, or
secondary deposits in the supraclavicular or para-aortic
lymph nodes or liver, also responded well to treatment,
with disappearance of metastatic deposits (clinically, radio-
logically and histologically) at the end of six cycles of
chemotherapy. Thus, intratumoural chemotherapy acted
both locally and systemically.
One patient with advanced neuroblastoma in group A
died during intratumoural chemotherapy because of
extensive primary disease. However, this patient had started
responding satisfactorily in terms of tumour regression.
The mortality was 5% in group A as compared to 20% in
group B, which was a statistically significant difference.
None of our patients treated with intratumoural chemother-
apy developed any metastasis during therapy, which sug-
gests that its systemic effect resulted from a sustained
release of drugs from the tumour to the circulation.
In terms of histopathology, 71% of patients in the
intratumoural chemotherapy group (A) responded well 
to treatment, compared with none in the intravenous
chemotherapy group (B). However, 21% in group A and
63% in group B showed a partial response. Eight percent
Table. Side effects of chemotherapeutic drugs
Wilms’ tumour*
Z (p)
Neuroblastoma*
Z (p)
Group A Group B Group A Group B
Nausea 4 (31) 10 (71) 2.307 (< 0.05) 3 (43) 4 (67) 0.888
Leucopenia (< 5,000/mm3) 1 (8) 6 (43) 2.378 (< 0.05) 2 (29) 2 (33) 0.183
Alopecia 2 (15) 9 (64) 3.037 (< 0.01) 4 (57) 4 (67) 0.358
Local pain 2 (15) – 1.54 1 (14) – 1.083
Colitis 1 (8) – 0.94 1 (14) – 1.083
Sterile pus 1 (8) – 1.085 – – –
Fever 3 (23) 5 (36) 0.728 1 (14) 3 (50) 1.457
Loss of appetite – 2 (14) 1.521 – 1 (17) 1.099
Blood transfusion 2 (15) 6 (43) 1.683 3 (43) 5 (83) 1.676
Stomatitis/mouth ulcer + skin rashes 2 (15) 5 (36) 1.261 – 2 (33) 1.734
*Data presented as n (%).
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Figure 5. Volume reduction after chemotherapy in both Wilms’
tumour and neuroblastoma.
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of patients in group A showed no response, compared
with 37% in group B. Histopathological response was
highly significant in those who responded well to treat-
ment (Figure 2).
The present study on intratumoural chemotherapy in
advanced solid tumours in children was conducted as a
pilot study and no reference data are available in the liter-
ature. In the present study, a fixed regimen of chemotherapy
that comprised vincristine, adriamycin and actinomycin
D was given intratumourally to patients with two types of
advanced-stage tumours, and the results were assessed clin-
ically, sonographically and histopathologically. Although
intravenous chemotherapy has been the conventional form
of treatment for advanced stage tumours, it is toxic in chil-
dren because of the high required doses, and mostly leads
to abandonment of therapy. Intratumoural chemotherapy
is superior to intravenous chemotherapy in terms of better
and earlier tumour regression, minimal side effects, better
tumour resectability and a good histopathological response.
This pilot study lays the foundation for treating in-
operable solid tumours in children with neoadjuvant
intratumoural chemotherapy, and proves its superiority
over the currently used intravenous chemotherapy. 
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